Price Chart

Key Stats

Net Expense Ratio Discount or Premium to NAV Total Assets Under Management 30-Day Average Daily Volume
0.58% -0.07% 272.64M 5704.70
Weighted Average Dividend Yield Turnover Ratio (Generic) 1 Year Fund Level Flows Max Drawdown (Since Inception)
0.35% 94.00% -38.59M Upgrade

Basic Info

Investment Strategy
The Fund seeks to track the investment results of the Dynamic Biotech & Genome Intellidex. The Fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the Underlying Intellidex in proportion to their weightings in the index.
General
Security Type Exchange-Traded Fund
Equity Style Mid Cap Growth
Broad Asset Class Sector Equity
Broad Category Equity
Global Peer Group Equity Sector Healthcare
Peer Group Health/Biotechnology Funds
Global Macro Equity Industry Sector
US Macro Sector Equity Funds
YCharts Categorization --
YCharts Benchmark --
Prospectus Objective Health/Biotechnology Funds
Fund Owner Firm Name Invesco
Broad Asset Class Benchmark Index
^MSWNTR 100.0%

View Basic Info
Start Trial

Performance Versus Peer Group

 
20%
15%
10%
5%
0
View Category Returns. Upgrade now.
Name
1M
3M
YTD
1Y
3Y
5Y
10Y
15Y
Total Return (Price)
--
--
--
--
--
--
--
--
Total Return (NAV)
--
--
--
--
--
--
--
--
Peer Group Rtn. (NAV)
--
--
--
--
--
--
--
--
% Rank in Peer Group (NAV)
--
--
--
--
--
--
--
--

Annual Total Returns Versus Peers

Loading chart...
Name
2019
2020
2021
2022
2023
2024
2025
YTD
18.65%
25.66%
1.54%
-10.83%
3.71%
1.10%
24.84%
1.13%
27.67%
15.90%
21.82%
-18.14%
23.79%
18.67%
21.09%
1.83%
22.31%
32.91%
3.04%
-23.34%
-6.23%
5.08%
-0.23%
4.54%
18.80%
33.66%
9.77%
-19.87%
5.15%
1.76%
18.83%
3.12%
4.65%
11.31%
14.58%
-2.16%
-2.18%
9.62%
27.97%
0.73%
32.56%
48.33%
-20.45%
-25.87%
7.60%
1.00%
35.88%
2.11%
As of January 10, 2026.

Asset Allocation

As of December 31, 2025.
Type % Net
Cash 0.07%
Stock 99.87%
Bond 0.04%
Convertible 0.00%
Preferred 0.00%
Other 0.02%
View Asset Allocation
Start Trial

Basic Info

Investment Strategy
The Fund seeks to track the investment results of the Dynamic Biotech & Genome Intellidex. The Fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the Underlying Intellidex in proportion to their weightings in the index.
General
Security Type Exchange-Traded Fund
Equity Style Mid Cap Growth
Broad Asset Class Sector Equity
Broad Category Equity
Global Peer Group Equity Sector Healthcare
Peer Group Health/Biotechnology Funds
Global Macro Equity Industry Sector
US Macro Sector Equity Funds
YCharts Categorization --
YCharts Benchmark --
Prospectus Objective Health/Biotechnology Funds
Fund Owner Firm Name Invesco
Broad Asset Class Benchmark Index
^MSWNTR 100.0%

View Basic Info
Start Trial

Top Portfolio Holders